GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
ELLIPTA™ vs. MDI Inhaler Preference Study, in Adult Subjects With Asthma
Completed
- Conditions
- Asthma
- Interventions
- Device: ELLIPTA inhalerDevice: Placebo Inhalation Aerosol (MDI)
- First Posted Date
- 2014-05-12
- Last Posted Date
- 2016-06-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 288
- Registration Number
- NCT02135718
- Locations
- 🇺🇸
GSK Investigational Site, San Antonio, Texas, United States
Study to Determine the Effect of Itraconazole on the Pharmacokinetics of Rilapladib (SB659032) in Healthy Volunteers
Phase 1
Withdrawn
- Conditions
- Alzheimer's Disease
- Interventions
- First Posted Date
- 2014-05-05
- Last Posted Date
- 2016-12-13
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT02130661
Investigation of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations
Phase 2
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-05-05
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 102
- Registration Number
- NCT02130193
- Locations
- 🇩🇪
GSK Investigational Site, Berlin, Germany
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Dose-Response Relationship of Multiple Doses of GSK2269557 Administered as a Dry Powder to Chronic Obstructive Pulmonary Disease (COPD) Patients
Phase 2
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: PLACEBODrug: GSK2269557 500 MCGDrug: GSK2269557 100 MCG
- First Posted Date
- 2014-05-05
- Last Posted Date
- 2018-10-11
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 64
- Registration Number
- NCT02130635
- Locations
- 🇩🇪
GSK Investigational Site, Berlin, Germany
A Phase 2B Open-Label, Single-Arm, Repeat-Dose Study to Evaluate the Reliability of an Autoinjector
Phase 2
Completed
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Device: Belimumab autoinjector
- First Posted Date
- 2014-04-28
- Last Posted Date
- 2018-04-11
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 95
- Registration Number
- NCT02124798
- Locations
- 🇺🇸
GSK Investigational Site, Beckley, West Virginia, United States
Evaluation of the Long-term Persistence of Hepatitis A Antibodies in Healthy Adults Who Were Vaccinated 21-25 Years Earlier With GlaxoSmithKline (GSK) Biologicals' Hepatitis A Vaccine, Havrix®
Phase 4
Withdrawn
- Conditions
- Hepatitis A
- Interventions
- Procedure: Blood sampling
- First Posted Date
- 2014-04-28
- Last Posted Date
- 2015-11-18
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT02124785
- Locations
- 🇧🇪
GSK Investigational Site, Wilrijk, Belgium
Belimumab Treatment Holiday and Treatment Re-start Study in Lupus Patients
- First Posted Date
- 2014-04-21
- Last Posted Date
- 2020-01-31
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 80
- Registration Number
- NCT02119156
- Locations
- 🇰🇷
GSK Investigational Site, Suwon, Kyonggi-do, Korea, Republic of
Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) -Study 2
Phase 3
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: FFDrug: VIDrug: PlaceboDrug: UMEC
- First Posted Date
- 2014-04-21
- Last Posted Date
- 2017-03-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 620
- Registration Number
- NCT02119286
- Locations
- 🇰🇷
GSK Investigational Site, Seoul, Korea, Republic of
The Effect of a Nutritional Supplement on Post Prandial Glucose and Lipids in an Adult Population
Not Applicable
Completed
- Conditions
- Impaired Fasting Glucose
- Interventions
- Dietary Supplement: 0% fibreDietary Supplement: 25% fibre
- First Posted Date
- 2014-04-21
- Last Posted Date
- 2015-05-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 96
- Registration Number
- NCT02119325
- Locations
- 🇮🇳
Lambda Therapeutic Research Ltd, Ahmedabad, Gujarat, India
A First Time in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2798745 in Healthy Subjects and Stable Heart Failure Patients
Phase 2
Completed
- Conditions
- Oedema, Pulmonary
- Interventions
- Drug: Placebo capsuleDrug: Placebo solutionDrug: Placebo suspension
- First Posted Date
- 2014-04-21
- Last Posted Date
- 2018-09-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 61
- Registration Number
- NCT02119260
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath